Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples